Details For Selected Brain Tumor Treatment

Sponsored By

Cedars-Siani Medical Center Brain Tumor Program

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303

		Phase:		Phase 3

		Treatment ID#:		1665 NTI 0501

		Age Group:		Adults Only

		Min Karnofsky Score:		50: Requires considerable assistance and frequent medical care

		Conditions:		Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed

		Last Updated:		03/01/2008

		Tumor Types:		Anaplastic Astrocytoma Any Malignant Brain Tumor Brainstem Glioma Germ Cell Tumors Gliosarcoma Metastatic Brain Tumor Oligodendroglioma High Grade


		Comments:		The purpose of this study is to examine the long-term safety and tolerability of human corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone (Decadron®) to treat peritumoral brain edema. This open-label, extended-use study is open to all patients who participate in either of the blinded studies, NTI 0302 or NTI 0303, including patients who may have discontinued blinded study medication early but completed the protocol-stipulated follow-up periods.

		Treatment Type:		Less-Toxics

		Contact:		Nina Paleologos MD Kellogg Cancer Care Center Evanston Hospital Contact: Pat Lada Evanston, IL USA Phone: 847-570-2025 Fax: E-mail: plada@enh.org Website:

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By